Appointment dossier — Uterine Leiomyosarcoma

Compounds studied in Uterine Leiomyosarcoma

• Cisplatin — Human evidence · 1 positive · PMID 37143137
• Olaparib — Human evidence · 1 positive · PMID 37143137
• Trastuzumab Deruxtecan — Human evidence · 1 positive · PMID 39639215
• Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215
• Resveratrol — Review evidence · 1 positive · PMID 28935150
• Bevacizumab — Review evidence · 0 positive · PMID 29759566
• Dacarbazine — Review evidence · 0 positive / 1 negative-mixed · PMID 24840518
• Doxorubicin — Review evidence · 0 positive / 1 negative-mixed · PMID 24840518
• Ifosfamide — Review evidence · 0 positive / 1 negative-mixed · PMID 24840518
• Nivolumab †Rx — Review evidence · 0 positive / 1 negative-mixed · PMID 30244960
• Pembrolizumab — Review evidence · 0 positive / 1 negative-mixed · PMID 30244960
• Selenium (Stand-alone) — Review evidence · 0 positive / 1 negative-mixed · PMID 33401525

“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.

Open recruiting trials (18)

• NCT06524583 · Phase 2 — Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour (France)
• NCT05649956 · Phase 2 — Letrozole in Uterine Leiomyosarcoma (United States)
• NCT07467772 · Phase 2 — Ph 2 Elacestrant in ER Positive Uterine Sarcomas (United States)
• NCT07262619 · Phase 1 / Phase 2 — EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors (United States)
• NCT01793168 — Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (United States)
• NCT04300556 · Phase 1 / Phase 2 — A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (United States)
• NCT05269381 · Phase 1 / Phase 2 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (United States)
• NCT05797168 · Phase 1 / Phase 2 — Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors (United States)
• NCT05208762 · Phase 1 — A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (United States)
• NCT06028724 — A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) (Italy)
• NCT04910802 · Phase 4 — Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden (Sweden)
• NCT05027776 · Phase 3 — Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years (China)
• NCT06277154 · Phase 2 — MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma (China)
• NCT06278857 · Phase 2 — SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) (Australia)
• NCT06289062 · Phase 2 — Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer (China)
• NCT05123482 · Phase 1 / Phase 2 — A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies (United States)
• NCT06630611 · Phase 2 — Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL) (Spain)
• NCT04038619 · Phase 1 — Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients (United States)

Most-relevant first: trials that name Uterine Leiomyosarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Interactions & safety to discuss

Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.

• Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
• Resveratrol × anticoagulants (high-stakes) — Monitor (moderate)
• Resveratrol × CYP3A4 substrates (high-stakes) — Monitor (low)
• Selenium (Stand-alone) × platinum_chemo (high-stakes) — Monitor (low)
• Nivolumab †Rx × Ipilimumab — Synergize (moderate)
• Nivolumab †Rx × corticosteroids — Use For IrAE (low)
• Resveratrol × Doxorubicin — Synergize (low)
• Selenium (Stand-alone) × antioxidants — Synergize (low)
• Selenium (Stand-alone) × Cisplatin — Synergize (low)

Financial help to look into

• PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
• HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
• CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
• Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
• NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/

For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.

Questions to ask your oncologist

1. I've read that Cisplatin has been studied in people for Uterine Leiomyosarcoma — what's the evidence, and is it an option or available in a trial for me?
2. I've read that Olaparib has been studied in people for Uterine Leiomyosarcoma — what's the evidence, and is it an option or available in a trial for me?
3. I've read that Trastuzumab Deruxtecan has been studied in people for Uterine Leiomyosarcoma — what's the evidence, and is it an option or available in a trial for me?
4. Of the open trials I found (for example NCT06524583), am I eligible for any — here or at a larger cancer center?
5. What is my exact diagnosis — the type, subtype, stage, and grade?
6. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
7. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
8. What is the goal of treatment for me — cure, long-term control, or comfort?
9. What are all of my standard treatment options, and what does each one involve?
10. What is the realistic benefit of each option, in actual numbers?
11. What are the most common and the most serious side effects, and how are they managed?
12. How will we know if treatment is working, and how often will I be scanned or tested?
13. If the first treatment doesn't work, what are the next options?
14. Are there gentler options if I want to prioritize quality of life?
15. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
16. Is my case reviewed by a multidisciplinary tumor board?
17. Would a second opinion at a center that treats my cancer often be worthwhile?
18. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
19. Which symptoms are emergencies, and who do I call after hours?
20. Should I see palliative or supportive care alongside my treatment?
21. How will treatment affect my daily life, work, and (if it matters to me) fertility?
22. What can I safely do myself — diet and activity — and is anything I'm taking risky?